For the year ending 2025-12-31, SLXNW had $4,807K increase in cash & cash equivalents over the period. -$10,828K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -11,912 |
| Depreciation | 14 |
| Share-based payment arrangement, noncash expense | 134 |
| Represent the amount of non cash loss upon entering transactions | 0 |
| Other non-cash financial expenses (income) | -344 |
| Loss (gain) on disposal of property and equipment | 0 |
| Loss from lease termination | 0 |
| Decrease (increase) in prepaid expenses | -396 |
| Decrease (increase) in other current assets | -13 |
| Increase (decrease) in accounts payable, trade | -142 |
| Increase (decrease) in operating lease liability | -5 |
| Increase (decrease) in employee related liabilities | 237 |
| Increase (decrease) in accrued liabilities | 102 |
| Net cash provided by (used in) operating activities | -10,819 |
| Investment in long-term deposits | 5 |
| Purchase of property and equipment | 9 |
| Net cash provided by (used in) investing activities | -14 |
| It represents the proceeds from issuance of ordinary shares upon public offering | 11,000 |
| Proceeds from issuance initial public offering | -1,530 |
| Proceeds from warrant exercises | 2,644 |
| Represents proceeds from issuance of ordinary shares upon warrants inducement | 5,036 |
| Issuance costs related to warrants inducement transactions | 740 |
| Represent the value of payment of underwriters promissory note | 696 |
| Represents the amount of prepaid of issuance cost related to at the market offering | 74 |
| Proceeds from stock options exercised | 0 |
| Cash acquired in excess of payments to acquire business | 0 |
| Net cash provided by (used in) financing activities | 15,640 |
| Cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), excluding exchange rate effect, including discontinued operation | 4,807 |
| Effect of exchange rate on cash, cash equivalents, restricted cash, and restricted cash equivalents, continuing operations | -2 |
| Balance of cash, cash equivalents and restricted cash at end of year | 1,270 |
| Balance of cash, cash equivalents and restricted cash at end of year | 6,075 |
Silexion Therapeutics Corp (SLXNW)
Silexion Therapeutics Corp (SLXNW)